Your browser doesn't support javascript.
loading
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier, Marie; Birsen, Rudy; Lauture, Laura; Mouche, Sarah; Angelino, Paolo; Dehairs, Jonas; Goupille, Léa; Boussaid, Ismael; Heiblig, Maël; Boet, Emeline; Sahal, Ambrine; Saland, Estelle; Santos, Juliana C; Armengol, Marc; Fernández-Serrano, Miranda; Farge, Thomas; Cognet, Guillaume; Simonetta, Federico; Pignon, Corentin; Graffeuil, Antoine; Mazzotti, Céline; Avet-Loiseau, Hervé; Delos, Océane; Bertrand-Michel, Justine; Chedru, Amélie; Dembitz, Vilma; Gallipoli, Paolo; Anstee, Natasha S; Loo, Sun; Wei, Andrew H; Carroll, Martin; Goubard, Armelle; Castellano, Rémy; Collette, Yves; Vergez, François; Mansat-De Mas, Véronique; Bertoli, Sarah; Tavitian, Suzanne; Picard, Muriel; Récher, Christian; Bourges-Abella, Nathalie; Granat, Fanny; Kosmider, Olivier; Sujobert, Pierre; Colsch, Benoit; Joffre, Carine; Stuani, Lucille; Swinnen, Johannes V; Guillou, Hervé; Roué, Gael.
Afiliación
  • Sabatier M; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Birsen R; LabEx Toucan, Toulouse, France.
  • Lauture L; Équipe Labellisée Ligue Nationale Contre le Cancer 2018, Toulouse, France.
  • Mouche S; Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva, and Swiss Cancer Center Leman, Geneva, Switzerland.
  • Angelino P; Université de Paris, Institut Cochin, CNRS U8104, Inserm U1016, Paris, France.
  • Dehairs J; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
  • Goupille L; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Paris, France.
  • Boussaid I; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Heiblig M; LabEx Toucan, Toulouse, France.
  • Boet E; Équipe Labellisée Ligue Nationale Contre le Cancer 2018, Toulouse, France.
  • Sahal A; Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva, and Swiss Cancer Center Leman, Geneva, Switzerland.
  • Saland E; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Santos JC; Laboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI-Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
  • Armengol M; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Fernández-Serrano M; LabEx Toucan, Toulouse, France.
  • Farge T; Équipe Labellisée Ligue Nationale Contre le Cancer 2018, Toulouse, France.
  • Cognet G; Université de Paris, Institut Cochin, CNRS U8104, Inserm U1016, Paris, France.
  • Simonetta F; Equipe Labellisée Ligue Nationale Contre le Cancer, Paris, France.
  • Pignon C; Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon, France.
  • Graffeuil A; CIRI, Inserm U1111 CNRS 5308, Université Lyon 1, Lyon, France.
  • Mazzotti C; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Avet-Loiseau H; LabEx Toucan, Toulouse, France.
  • Delos O; Équipe Labellisée Ligue Nationale Contre le Cancer 2018, Toulouse, France.
  • Bertrand-Michel J; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Chedru A; LabEx Toucan, Toulouse, France.
  • Dembitz V; Équipe Labellisée Ligue Nationale Contre le Cancer 2018, Toulouse, France.
  • Gallipoli P; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Anstee NS; LabEx Toucan, Toulouse, France.
  • Loo S; Équipe Labellisée Ligue Nationale Contre le Cancer 2018, Toulouse, France.
  • Wei AH; Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain.
  • Carroll M; Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain.
  • Goubard A; Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute, Badalona, Spain.
  • Castellano R; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Collette Y; LabEx Toucan, Toulouse, France.
  • Vergez F; Équipe Labellisée Ligue Nationale Contre le Cancer 2018, Toulouse, France.
  • Mansat-De Mas V; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Bertoli S; LabEx Toucan, Toulouse, France.
  • Tavitian S; Équipe Labellisée Ligue Nationale Contre le Cancer 2018, Toulouse, France.
  • Picard M; Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva, and Swiss Cancer Center Leman, Geneva, Switzerland.
  • Récher C; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Bourges-Abella N; Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'Hématologie, Toulouse, France.
  • Granat F; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Kosmider O; Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'Hématologie, Toulouse, France.
  • Sujobert P; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Colsch B; Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'Hématologie, Toulouse, France.
  • Joffre C; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5077, Toulouse, France.
  • Stuani L; Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service d'Hématologie, Toulouse, France.
  • Swinnen JV; MetaboHUB-MetaToul, National Infrastructure of Metabolomics and Fluxomics, University Paul Sabatier, Toulouse, France.
  • Guillou H; MetaboHUB-MetaToul, National Infrastructure of Metabolomics and Fluxomics, University Paul Sabatier, Toulouse, France.
  • Roué G; Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, MetaboHUB, Gif sur Yvette, France.
Cancer Discov ; 13(7): 1720-1747, 2023 07 07.
Article en En | MEDLINE | ID: mdl-37012202
ABSTRACT
Although transcription factor CCAAT-enhancer binding protein α (C/EBPα) is critical for normal and leukemic differentiation, its role in cell and metabolic homeostasis is largely unknown in cancer. Here, multiomics analyses uncovered a coordinated activation of C/EBPα and Fms-like tyrosine kinase 3 (FLT3) that increased lipid anabolism in vivo and in patients with FLT3-mutant acute myeloid leukemia (AML). Mechanistically, C/EBPα regulated the fatty acid synthase (FASN)-stearoyl-CoA desaturase (SCD) axis to promote fatty acid (FA) biosynthesis and desaturation. We further demonstrated that FLT3 or C/EBPα inactivation decreased monounsaturated FA incorporation to membrane phospholipids through SCD downregulation. Consequently, SCD inhibition enhanced susceptibility to lipid redox stress that was exploited by combining FLT3 and glutathione peroxidase 4 inhibition to trigger lipid oxidative stress, enhancing ferroptotic death of FLT3-mutant AML cells. Altogether, our study reveals a C/EBPα function in lipid homeostasis and adaptation to redox stress, and a previously unreported vulnerability of FLT3-mutant AML to ferroptosis with promising therapeutic application.

SIGNIFICANCE:

FLT3 mutations are found in 30% of AML cases and are actionable by tyrosine kinase inhibitors. Here, we discovered that C/EBPα regulates FA biosynthesis and protection from lipid redox stress downstream mutant-FLT3 signaling, which confers a vulnerability to ferroptosis upon FLT3 inhibition with therapeutic potential in AML. This article is highlighted in the In This Issue feature, p. 1501.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Ferroptosis Límite: Humans Idioma: En Revista: Cancer Discov Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Ferroptosis Límite: Humans Idioma: En Revista: Cancer Discov Año: 2023 Tipo del documento: Article País de afiliación: Francia